LETTER FROM EXECUTIVE DIRECTOR

Merriam-Webster defines the word momentum as “strength or force gained by motion or by a series of events.” Indeed, momentum is the perfect word to describe NAF’s 2022. The pace of activity throughout the Ataxia community is accelerating, affecting all aspects of the work that we do. To put it succinctly, lots of good stuff is happening!

Let me provide you several examples of the positive momentum this past year at NAF:

• The addition of Dr. Lauren Moore as NAF’s first Chief Scientific Officer has helped raise NAF’s profile at scientific meetings and created the strategic capability to maximize the impact of our more than two million dollars of annual Ataxia research funding.

• We have taken advantage of the increasing familiarity with video conferencing technology to offer a growing number of high interest webinars, virtual support groups, and another well attended virtual Annual Ataxia Conference. We are thrilled that this allows even more members of our community to participate in our programming.

• Our dedicated advocacy work has led to the inclusion of “heredity ataxia” in the important Congressionally Directed Medical Research Program, opening up the potential for millions of dollars of additional funding for critical research annually.

• We launched our first annual fund campaign, ACCELERATE!, with a focus on engaging more donors in the NAF story and the impact their support has on our programming.

• And finally, we have worked more closely with our pharmaceutical partners than ever before, and the NAF Drug Development Collaborative had a very strong 2022 with ten pharma members. The Ataxia community is celebrating the first approved treatment for any type of Ataxia, in this case Friedreich's Ataxia, that occurred in the first quarter of 2023.

With all of this good stuff comes a heartfelt THANK YOU to you, our loyal donors. Your generosity led NAF to another record year in terms of philanthropic support which allows us to continue to grow our programming. We simply could not do it without you.

I close with a challenge to each of you. How will you participate in this forward momentum? There are so many different ways to be involved with NAF, and I invite you to explore and reach out to us in 2023.

With gratitude,

Andrew Rosen,
Executive Director
## NAF Membership + 2022 At a Glance

### Total Members

- **11,733** Total Members
- **51% growth** from last year

### About Our Members

<table>
<thead>
<tr>
<th>Category</th>
<th>Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>Person with Ataxia</td>
<td>6,210</td>
</tr>
<tr>
<td>At-Risk for Ataxia</td>
<td>668</td>
</tr>
<tr>
<td>Family Member of Person with Ataxia</td>
<td>3,300</td>
</tr>
</tbody>
</table>

### Friend, Professional, and Support Group Members

<table>
<thead>
<tr>
<th>Role</th>
<th>Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>Friend of Person with Ataxia</td>
<td>447</td>
</tr>
<tr>
<td>Ataxia Professional</td>
<td>231</td>
</tr>
<tr>
<td>Ataxia Researcher</td>
<td>465</td>
</tr>
<tr>
<td>Nonprofit Professional</td>
<td>87</td>
</tr>
<tr>
<td>Ataxia Clinician</td>
<td>238</td>
</tr>
<tr>
<td>Pharmaceutical Professional</td>
<td>87</td>
</tr>
</tbody>
</table>

### 2022 At-A-Glance

<table>
<thead>
<tr>
<th>Category</th>
<th>Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>New Members at NAF</td>
<td>3,961</td>
</tr>
<tr>
<td>Research Initiatives Funded</td>
<td>12</td>
</tr>
<tr>
<td>Total Spent on Research</td>
<td>$2,781,424</td>
</tr>
<tr>
<td>NEW participants in the Natural History Study</td>
<td>143</td>
</tr>
<tr>
<td>Support Group Meetings</td>
<td>415</td>
</tr>
<tr>
<td>Meetings with Members of Congress</td>
<td>79</td>
</tr>
<tr>
<td>Webinars Hosted</td>
<td>16</td>
</tr>
<tr>
<td>Drug Development Collaborative Members</td>
<td>10</td>
</tr>
</tbody>
</table>
COMMUNITY PROGRAMS AND SERVICES IMPACT

NAF supports those impacted by Ataxia and their families in a number of ways, including education, advocacy, and community events that foster a spirit of connection and learning to live better with Ataxia.

SUPPORT GROUPS
Connecting people affected by Ataxia to improve lives.

NAF coordinates Support Groups as a way for the Ataxia community to connect and learn from others. They ensure that nobody has to experience Ataxia alone. Our volunteer Support Group Leaders provide this invaluable service to the community.

Support Groups
2 Groups returning with new leadership
3 New groups added

Support Group Meetings
57% more meetings than 2021

Pamela Kahn
San Diego Ataxia Support Group Leader

Pamela is a proud resident of San Diego, California who is deeply passionate about many things including traveling with her husband, expressing her creativity through artwork, and most importantly, advocating for herself and others sharing her experiences. Pamela is a strong advocate for the American Heart Association as well as the National Ataxia Foundation.

Pamela’s Ataxia journey began very suddenly in October of 2020. In the midst of the pandemic, Pamela was hospitalized and the symptoms she was experiencing led her to an Ataxia diagnosis. She described this time as incredibly lonely and isolating and immediately began researching Ataxia online, before even leaving the hospital.

After about a year and a half of trying to grasp her new way of living, Pamela had an intense desire to connect with others around her who may have been feeling the same way and were in search of support. Unfortunately, there were no support groups in San Diego at the time, but she didn’t let that stop her.

Pamela says that connecting people together is one of her specialties and with the help of a few friends in the area, began the San Diego Support Group. Pamela is such an enthusiastic leader and is excited to see what the future holds for this amazing group of people!
Thank you advocates! Your courageous efforts to share your story with lawmakers is making a difference for the Ataxia community.

Advocacy
Amplifying the voice of the Ataxia community.

NAF’s advocacy activities expand our partnerships with other organizations and policy makers to help make a difference for people affected by Ataxia. Involvement in advocacy gives us a way to get our community’s stories to policy makers and pharmaceutical companies to grow awareness, accelerate drug development, and ensure access to care and treatment services.

The decision from Congress to add “Hereditary Ataxias” into the CDMRP was a milestone for Ataxia advocacy. It is a crucial step towards NAF’s mission to accelerate treatment development for Ataxia. It shows how impactful advocacy efforts can be. I am grateful for all the Ataxia community members who joined NAF and FARA to lobby for this change to CDMRP appropriations. This will open the door to more funding for our Ataxia researchers.”

— Lori Shogren, Community Program and Services Director

2022 Advocacy Accomplishments

“Hereditary Ataxia” added into the Congressionally Directed Medical Research Program for FY23

6 Friedreich’s Ataxia grants recommended for CDMRP/PRMRP FY22 funding totaling over $14 million

Senate Resolution 850 to designate September 25th as National Ataxia Awareness Day was passed

Ataxia Hill Day was held on September 21st

Ataxia Hill Day

NAF and FARA coordinated the 4th United Against Ataxia Hill Day on September 21, 2022 to meet with legislators about issues important to the Ataxia community. Our efforts made a big impact!

2,933 NAF members signed up for our advocacy email list

88 Ataxia advocates

31 States & DC represented

79 Congressional meetings

49 Senate

30 House

51 Democrat offices

27 Republican offices

1 Independent office
ANNUAL ATAXIA CONFERENCE

Bringing the community together to accelerate treatment development and improve quality of life for those with Ataxia.

The Annual Ataxia Conference is more than just a conference. It’s a gathering place where Ataxia clinicians share strategies to help you manage care, people network with peers and build relationships that last far beyond the conference, and everyone works together to accelerate treatment development. 2022’s virtual AAC allowed attendees from all over the world to come together to learn more.
NAF supports Ataxia research in a variety of ways, including direct funding, drug development collaboration, education for neurologists, and providing professional networking opportunities for researchers and clinicians.

**NAF RESEARCH GRANTS**

*Accelerating Ataxia treatment development.*

Ataxia impacts every aspect of a person’s life – and we need solutions. Research and drug development will provide those solutions. NAF approved funding for 16 out of 86 Ataxia research grants reviewed in 2022.

- $850,000 Funded Overall
- 30% increase from last year
- 16 Research studies supported
  - 7 Seed Money Grants
  - 4 Young Investigator Awards
  - 3 Post Doc Fellowship
  - 2 Pioneer SCA Translational Award
  - 1 Pre-Doctoral Fellowship to Promote Diversity in Ataxia Research
- 144 Participants enrolled in the Brain Donation Program
  - 42 enrolled in 2022
  - 8 donation samples provided to researchers

**RESEARCHER SPOTLIGHT**

Vanessa Sanchez fell in love with cellular and molecular neurobiology during her last two years at California State University, Fullerton. She currently works in the lab of Dr. Naiara Akizu at UPenn and the Children's Hospital of Philadelphia. She is fascinated by how our brain cells (neurons) can adapt to our environment and just “know” what to do. Ms. Sanchez received a Diverse Scientists in Ataxia Pre-doctoral Research Fellowship from NAF for her research study on SCAR20.

“I am deeply committed to advocating for females and underrepresented minorities, like myself, in STEM and academia, as well as bringing scientific knowledge to the public through various forms of outreach activities. While I am deeply involved in many outreach organizations that represent the face of minority students, such as Penn INSPIRE, LAGAPSA, and EE Just Biomedical Society, I also serve many leadership roles within NGG’s Graduate-Led Initiatives and Activities Committee (GLIA). I am also a science writer for NGG’s Penn Neuro Know’s blog and serve as Co-Chair for Penn’s Neuroscience Public Lecture as a means to extend the accessibility of neuroscience research performed on campus to the broader Philadelphia community.”

NAF is proud to support efforts being made in the Ataxia research community!
EDUCATING NEUROLOGISTS

Improving clinical care for Ataxia patients.

There is a shortage of well-trained specialists who are knowledgeable about clinical and scientific aspects of Ataxia. NAF is committed to educating health care providers so patients and families can find the care they need.

ATAXIA CLINICAL TRAINING (ACT)

NAF sponsored the first ACT in 2022. The program was developed for clinician-scientists committed to improving the lives of patients and caregivers affected with Ataxia.

- 31 Movement Disorder Fellows attended
- 1 Neurologist attended
- 15 Leading Ataxia experts provided lectures
- 16 States represented
- 3 International Attendees

“We must press on in our endeavors to train specialists who will provide the best treatment to people affected by Ataxia. There is no better way to serve the Ataxia community than to educate health care providers who are enthusiastic about moving the Ataxia needle forward.”

—Pravin Khemani, MD, ACT Chair • Movement Disorder Neurologist
Swedish Neuroscience Specialists • Member NAF Medical Research Advisory Board

ATAXIA CENTERS OF EXCELLENCE (ACE)

In our continued commitment to improving clinical care and accelerating treatment development, in 2022 NAF opened applications for its new Ataxia Centers of Excellence (ACE) designation in 2022.

The ACE program will recognize exceptional centers providing comprehensive care and services for individuals affected by Ataxia and their families. First ACE designations will be awarded in 2023. Centers will:

• Provide expert clinical care for Ataxia and Ataxia-related disorders
• Engage in clinical research and/or clinical trials
• Provide education to patients and their families in the areas they serve
• Work with NAF locally and nationally in its efforts to continually improve the lives of those affected by Ataxia
**AMERICAN ACADEMY OF NEUROLOGY (AAN)**

NAF made sure that Ataxia is a part of the conversation with thousands of neurologists who attended the 2022 American Academy of Neurology Meeting. At our exhibit, NAF’s Chief Scientific Officer and other research department staff represented the Ataxia community and connected with researchers and clinicians to teach them about Ataxia.

---

**CREATING OPPORTUNITIES FOR SCIENTIFIC COLLABORATION**

*Accelerating development of treatments and a cure.*

---

**INTERNATIONAL CONGRESS FOR ATAXIA RESEARCH (ICAR)**

*Global collaboration to inspire research innovation.*

ICAR is a collaborative research environment that promotes exchange of ideas and knowledge to improve understanding of Ataxias and accelerate treatment development initiatives. The inaugural event was the largest-ever international conference for Ataxia researchers!

<table>
<thead>
<tr>
<th>458 Delegates</th>
<th>110 Oral Presentations</th>
</tr>
</thead>
<tbody>
<tr>
<td>32 States</td>
<td>200+ Poster Presenters</td>
</tr>
<tr>
<td>19 Countries</td>
<td>330 Abstract Submissions</td>
</tr>
<tr>
<td>92% Found the conference very useful for advancing their work in Ataxia research</td>
<td></td>
</tr>
</tbody>
</table>

---

“ICAR was an incredible opportunity to interact with not only the leading experts in ataxia research, but also the patients whose lives we are always aiming to improve. In addition to the interesting research lectures and posters provided by institutions across the world, ICAR provided great opportunities to network with other researchers at the beginning of their careers and at the top of the field. Looking forward to the next one in London 2024!”

— Alejandro Rey Hipolito, Graduate Student, An ICAR Top Poster Presenter Winner, Baylor College of Medicine
NAF DRUG DEVELOPMENT COLLABORATIVE
Connecting those involved in Ataxia drug development.

The NAF Drug Development Collaborative (DDC) addresses shared challenges and opportunities in Ataxia therapy development. The Collaborative provides a centralized source of Ataxia expertise, patient registry and natural history data plus a collection of curated/annotated biospecimens to support preclinical and clinical R&D.

<table>
<thead>
<tr>
<th>Members</th>
<th>10</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 New Members in 2022</td>
<td></td>
</tr>
</tbody>
</table>

| Exclusive Industry Roundtables | 11 |

| DDC Advisory Committee Meetings | 5 |

Funding from DDC helped support:
- Substantial growth in the CRC-SCA natural history study
- Launch of NAF’s no-cost genetic counseling and testing initiative

Thank You DDC Members!

CLINICAL RESEARCH CONSORTIUM FOR THE STUDY OF CEREBELLAR ATAXIA (CRC-SCA)
Natural history study and biomarker identification to accelerate treatment development.

The CRC-SCA is a collaborative group of Ataxia researchers with a mission to better understand factors that determine Ataxia progression. They seek to improve understanding of the disease process and help with developing treatments. They coordinate a natural history study of Cerebellar Ataxias that has been important to advancements being made toward drug development.

874 Participants

30% increase in participants!

143 Enrolled in 2022

14 Sites

Ataxia types studied
(SCA1, 2, 3, 6, 7, 8, and 10)

“With over 800 participants, the CRC-SCA study is the largest ongoing natural history study enrolling patients with the most frequently occurring spinocerebellar ataxias and has followed individuals for more than 10 years. Such studies help to understand the characteristics of disease progression, and are invaluable tools to guide the design of clinical efficacy studies.”

—Christian Rummey, PhD • CRC-SCA Data Scientist and Biostatistician
SCAsource PARTNERSHIP

SCAsource makes research more accessible and understandable to Ataxia patients and families. They provide peer-reviewed articles written by scientists for the patient audience. SCAsource entered a partnership with NAF in 2022 to host their articles.

“NAF has supported me at multiple stages of my postdoc, and I don’t think I’d be where I’m at in my career without the support you’ve given to my work.”
— Collin Anderson, PhD, NAF Grant Recipient

“Receiving the NAF Young Investigator SCA Award made it possible to implement a concrete scientific project independently and autonomously...Our research has direct impact on improving trial-readiness for patients.”
— Jennifer Faber, MD, NAF Grant Recipient

GENETIC COUNSELING AND TESTING INITIATIVE
Removing barriers to pursuing genetic testing for Ataxia.

In 2022, NAF launched a genetic counseling and testing program for individuals at-risk for SCAs 1, 2, and 3. The program is offered at no cost to the participant and health insurance is not required.

114 patients served, providing:
158 counseling sessions
80 genetic tests

97% of participants would recommend the program to family
Thanks to Donors

As you can see, 2022 included many accomplishments that are accelerating treatment development and improving the lives of those living with Ataxia. These accomplishments are a direct result of the generosity of our donors! Our donors make it possible for NAF to continue to deliver on our mission. Thank you!

Donors by Gift Size

3,892 Total Donors
$3,415,895 Total Donated

- 1772 $10,000+
- 1676 $5,000-$9,999
- 193 $1,000-$4,999
- 180 $500-$999
- 44 $1-$99
- 27 $100-$499

REVENUE AND FUNDRAISING

Thanks to Donors

As you can see, 2022 included many accomplishments that are accelerating treatment development and improving the lives of those living with Ataxia. These accomplishments are a direct result of the generosity of our donors! Our donors make it possible for NAF to continue to deliver on our mission. Thank you!
NAF partners with a variety of corporations. We would like to recognize our corporate partners who provided much needed support.

**Corporate Partners**

$25,000+
- Biogen
- Biohaven Pharmaceuticals
- PTC Therapeutics
- Reata Pharmaceuticals Inc.
- Seelos Therapeutics
- Takeda Pharmaceuticals USA, Inc.
- Vico Therapeutics B.V.
- DTx Pharma
- Horizon Pharma USA, Inc.
- Lacerta Therapeutics
- Servier Pharmaceuticals
- Stealth BioTherapeutics
- Priority Courier Experts
- F. Hoffman-LaRoche Ltd

$10,000 - $24,999
- Design Therapeutics
- Epic Games
- Pfizer

$5,000 - $9,999
- Google
- Jackson National Life Insurance
- Massachusetts Mutual Life Insurance Company
- SEM Dynamics
- Torres Electrical Supply Co, Inc.

$2,500 - $4,999
- Destroyer Park Golf
- First New York Federal Credit Union
- Golf Planner Pro, LLC

**Foundations**

NAF received grants from various foundations in 2022. We thank them for the opportunity and their support and commitment to our mission.

$100,000+
- Albuquerque Community Foundation
- Templeton Estate Fund
- The Clementz Foundation
- The Cossack Family Foundation
- The Gordon and Marilyn Macklin Foundation

$10,000 - $99,999
- Haider Quality Freedom Foundation
- Don & Jodi Heeringa Family Fund
- PSEG Foundation

$5,000 - $9,999
- William S. Butterfield Trust

$2,500 - $4,999
- Ataxia Foundation Ireland
- Brothers On A Quest, Inc
- Community Health Charities
- EveryLife Foundation
- Lincoln Financial Foundation Inc.

**Community Giving Platforms**

NAF does not receive individual donor information from third-party giving platforms. We do want to recognize the individuals who supported us through a community giving platform. Thank you for your generous contributions!

$100,000+
- Benevity Community Fund
- Facebook
- Fidelity Charitable

$2,500 - $4,999
- Burnt Hills - Ballston Lake School District
- Schwab Charitable
- YourCause

$1,000 - $2,499
- Bank of America Employee Giving Campaign
- Network for Good
- Paypal Giving Fund
We are humbled by our generous donors who supported our work in 2022. These individuals stepped forward to make sure that NAF can continue to lead efforts to accelerate development of treatments for Ataxia and improve the lives of those living with the disease. The caring individuals who contributed $1,000 or more are listed below.

<table>
<thead>
<tr>
<th>Amount Range</th>
<th>Donors</th>
</tr>
</thead>
<tbody>
<tr>
<td>$50,000+</td>
<td>Michael M Anderson Estate, John Patterson Estate, Marcia Neugebauer, Kathleen and John Schnobrich Anonymous</td>
</tr>
<tr>
<td>$25,000 - $49,999</td>
<td>Susan Huffman, Gregory Klassen James Keene</td>
</tr>
<tr>
<td>$5,000 - $9,999</td>
<td>Peter &amp; Susan Agostini, Marsha Asp, Richard and Lois Bierschbach, Dorothy Bowdon, Karen Brown, Judith Chronister Ruth Coffey, Brian Covington, Sandra Johnson Roger Kaufman Eugene and Margaret Klingberg, Darrell Knutie Jennifer Leader Mark Machado, John Maxwell, Robert Metcaif, Jeanette Pinkney, Gwen &amp; Art Pinkston, Laura Ranum PhD, Bruce &amp; Susan Ruehl, Sylvia Shelstad, Linda Snider-Sidwell and Mark Sidwell, Maryann Sweeney &amp; John Dwyer, Michael and Janet Sweeney</td>
</tr>
</tbody>
</table>
**Impact Partners**

Impact Partners are a passionate and determined group of monthly givers who are on a mission to find a cure for Ataxia in our lifetime. Impact Partners are people who give what they can to help us offer Ataxia research grants, provide educational programs for Ataxia families, and offer support services in local communities around the country. Thank you for your consistent support in 2022!

107 Monthly donors

$66,033 Raised

↑ 59% increase

**Accelerate!**

Accelerate is a community-driven fundraising program designed to speed up our advocacy efforts, including: new legislation important to our community and progress, adding more resources for the 65+ support groups, educate our community about genetic testing including providing genetic counseling and testing for all those living with Ataxia, and creating Ataxia awareness to improve the understanding of Ataxia.

397 Donors

$235,761 Raised

**Mark and Leah Minkin**

Mark and Leah Minkin joined Accelerate! as 2022 National Co-Chairs of the campaign. Mark said that when Leah was diagnosed with Ataxia, it “hit us hard. I decided that I need to do more.” They encouraged others to get involved with Accelerate! and reached out to many in their community. Mark and Leah also hosted a bowling tournament that raised more than $18,000! Thank you, Mark and Leah! Your passion for making a difference is an inspiration!

**Walk N’ Roll Cities**

Walk N’ Rolls are fundraisers organized by volunteers in their local communities. Thank you to everyone who organized, donated, and/or attended these impactful events!

14 Walks

$250,665 Raised

1712 Donations

**Walk N’ Roll Cities**

Chicago
Kansas City
Hampton Roads/Richmond
Minneapolis
Sioux Empire
Central PA
Massachusetts
North Carolina
Pittsburgh
Tri-State
Treasure Coast
Orange County
Utah
Western Washington
Many thanks to the individuals or groups who turned their passions into a community fundraising event for a good cause! These events raise money in support of NAF’s mission to accelerate the development of treatments while improving the lives of those living with Ataxia. Thank you for the generous donations and time spent organizing the events.

**16 Passion Fundraisers**

$112,810 Raised

**FUNDRAISER SPOTLIGHT**

NAF fundraisers take something that they are passionate about and turn it into a fundraiser. Their efforts work towards our mission to accelerate treatment development and improve the lives of those living with Ataxia. Pam Legare hosted her first-ever passion fundraiser in 2022. She used her love of volleyball and passion for participating in tournaments to raise money for NAF in honor of her husband, Steve, who has acquired Ataxia.

Serving Up a Cure for Ataxia Volleyball Tournament was held on June 11th in Chepachet, RI. The event raised more than $5,000! A fun day for Pam’s community supported those who live with Ataxia in a big way!
WORKING TOWARDS A CURE

SUPPORT & REVENUE

<table>
<thead>
<tr>
<th>Source</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contributions</td>
<td>$3,415,895</td>
</tr>
<tr>
<td>Research Collaborative</td>
<td>$800,000</td>
</tr>
<tr>
<td>Conference Income</td>
<td>$309,574</td>
</tr>
<tr>
<td>Other Income</td>
<td>-$127,884</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$4,397,585</strong></td>
</tr>
</tbody>
</table>

EXPENSES

<table>
<thead>
<tr>
<th>Expense</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research</td>
<td>$1,837,520</td>
</tr>
<tr>
<td>Education and Service</td>
<td>$579,104</td>
</tr>
<tr>
<td>Drug Development Collaborative</td>
<td>$943,904</td>
</tr>
<tr>
<td>Management and General</td>
<td>$377,042</td>
</tr>
<tr>
<td>Fundraising</td>
<td>$393,619</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$4,131,189</strong></td>
</tr>
</tbody>
</table>

NET ASSETS

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Change in Net Assets</td>
<td>$266,396</td>
</tr>
<tr>
<td>Net Assets, beginning</td>
<td>$4,160,221</td>
</tr>
<tr>
<td>Net Assets, ending</td>
<td>$4,426,617</td>
</tr>
<tr>
<td>Total Liabilities</td>
<td>$581,978</td>
</tr>
<tr>
<td>Total Net Assets</td>
<td>$5,008,595</td>
</tr>
</tbody>
</table>

HOW WE FURTHER OUR MISSION

- Research: 44%
- Drug Development Collaborative: 23%
- Education & Service: 14%
- Management & General: 9%
- Fundraising: 10%

Fundraising 10%
Management & General 9%
Drug Development Collaborative 23%
Research 44%
Education & Service 14%
## Organization Leadership

### Board of Directors

<table>
<thead>
<tr>
<th>Position</th>
<th>Name</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>President</td>
<td>Sam Kirton</td>
<td>Fairfax, VA</td>
</tr>
<tr>
<td>Vice President</td>
<td>Linda Snider-Sidwell, MD</td>
<td>Omaha, NE</td>
</tr>
<tr>
<td>Treasurer</td>
<td>Greg Rooks</td>
<td>Atlanta, GA</td>
</tr>
<tr>
<td>Secretary</td>
<td>John Mauro</td>
<td>Auburn, MA</td>
</tr>
<tr>
<td>Executive Committee</td>
<td>David Brunnert</td>
<td>Houston, TX</td>
</tr>
<tr>
<td>Directors</td>
<td>Michael Cammer</td>
<td>Downington, PA</td>
</tr>
<tr>
<td></td>
<td>Cindy DeMint</td>
<td>Yorba Linda, CA</td>
</tr>
<tr>
<td></td>
<td>John Dwyer</td>
<td>Minneapolis, MN</td>
</tr>
<tr>
<td></td>
<td>Serena Hung</td>
<td>Watertown, MA</td>
</tr>
<tr>
<td></td>
<td>Jim Keene</td>
<td>Atherton, CA</td>
</tr>
<tr>
<td></td>
<td>Greg Klassen</td>
<td>Elkridge, MD</td>
</tr>
<tr>
<td></td>
<td>Denise Kolpack</td>
<td>Fargo, ND</td>
</tr>
<tr>
<td></td>
<td>Ann Riley</td>
<td>Washington, DC</td>
</tr>
<tr>
<td></td>
<td>Laura Ranum, PhD</td>
<td>Fargo, ND</td>
</tr>
<tr>
<td></td>
<td>Liana Rosenthal, MD</td>
<td>Baltimore, MD</td>
</tr>
<tr>
<td></td>
<td>Tetsuo Ashizawa, MD</td>
<td>Minneapolis, MN</td>
</tr>
<tr>
<td></td>
<td>Larry Schut, MD</td>
<td>Maple Lake, MN</td>
</tr>
<tr>
<td></td>
<td>Harry T. Orr, PhD</td>
<td>Minneapolis, MN</td>
</tr>
<tr>
<td></td>
<td>Susan Perlman, MD</td>
<td>Los Angeles, CA</td>
</tr>
<tr>
<td></td>
<td>Beverly Davidson, PhD</td>
<td>Minnetonka, MN</td>
</tr>
<tr>
<td></td>
<td>Larry Schut, MD</td>
<td>Minneapolis, MN</td>
</tr>
<tr>
<td></td>
<td>Vikram Shakkottai, MD</td>
<td>Dallas, TX</td>
</tr>
</tbody>
</table>

### Medical and Research Advisory Board

<table>
<thead>
<tr>
<th>Role</th>
<th>Name</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chair of MRAB</td>
<td>Vikram Shakkottai, MD, PhD</td>
<td>University of Texas Southwestern</td>
</tr>
<tr>
<td>Research Director</td>
<td>Laura Ranum, PhD</td>
<td>University of Florida, College of Medicine</td>
</tr>
<tr>
<td>Medical Director</td>
<td>Liana Rosenthal, MD</td>
<td>Johns Hopkins University</td>
</tr>
<tr>
<td></td>
<td>Tetsuo Ashizawa, MD</td>
<td>Methodist Hospital Research Institute</td>
</tr>
<tr>
<td></td>
<td>Khalaf Bushara, MD</td>
<td>University of Minnesota</td>
</tr>
<tr>
<td></td>
<td>Beverly Davidson, PhD</td>
<td>Children’s Hospital of Philadelphia</td>
</tr>
<tr>
<td></td>
<td>Brent L. Fogel, MD</td>
<td>University of California, Los Angeles</td>
</tr>
<tr>
<td></td>
<td>Chris M. Gomez, MD</td>
<td>University of Chicago</td>
</tr>
<tr>
<td></td>
<td>Sheng Han Kuo, MD</td>
<td>Columbia University</td>
</tr>
<tr>
<td></td>
<td>Pravin Khemani, MD</td>
<td>Swedish Neuroscience Institute</td>
</tr>
<tr>
<td></td>
<td>Albert La Spada, MD</td>
<td>University of California Irvine School of Medicine</td>
</tr>
<tr>
<td></td>
<td>David Lynch, MD</td>
<td>University of Pennsylvania</td>
</tr>
<tr>
<td></td>
<td>Puneet Opal, MD</td>
<td>Northwestern University Feinberg School of Medicine</td>
</tr>
<tr>
<td></td>
<td>Harry T. Orr, PhD</td>
<td>University of Minnesota</td>
</tr>
<tr>
<td></td>
<td>Gülün Öz, PhD</td>
<td>University of Minnesota Center for Magnetic Resonance Research</td>
</tr>
<tr>
<td></td>
<td>Henry Paulson, MD</td>
<td>University of Michigan Medical Center</td>
</tr>
<tr>
<td>Ex Officio Board Member</td>
<td>Harry T. Orr, PhD</td>
<td>Minneapolis, MN</td>
</tr>
<tr>
<td></td>
<td>Larry Schut, MD</td>
<td>Minneapolis, MN</td>
</tr>
<tr>
<td></td>
<td>Vikram Shakkottai, MD</td>
<td>Dallas, TX</td>
</tr>
<tr>
<td></td>
<td>Susan Perlman, MD</td>
<td>Los Angeles, CA</td>
</tr>
<tr>
<td></td>
<td>Stefan Puls, MD</td>
<td>University of Utah Health Sciences Center</td>
</tr>
<tr>
<td></td>
<td>Jeremy D. Schmahmann, MD, FAAN, FANPA</td>
<td>Harvard Medical School</td>
</tr>
<tr>
<td></td>
<td>Larry Schut, MD</td>
<td>University of Minnesota</td>
</tr>
<tr>
<td></td>
<td>S.H. Subramony, MD</td>
<td>University of Florida</td>
</tr>
<tr>
<td></td>
<td>George “Chip” Wilmot, MD, PhD</td>
<td>Emory University</td>
</tr>
<tr>
<td></td>
<td>Robert B. Wilson, MD</td>
<td>University of Pennsylvania</td>
</tr>
</tbody>
</table>
To our donors, community members, partners, and Ataxia professionals, we thank you for making 2022 a successful year. Your support and participation are key to accelerating the development of treatments for Ataxia.